Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

sections

Contraception

ellaOne emergency contraception available for sale through UK pharmacies

Women are now able to buy the emergency contraceptive ellaOne (ulipristal acetate, 30mg) from UK pharmacies without a prescription, its manufacturer has confirmed.

The drug was granted marketing authorisation as a non-prescription medicine in the EU in January 2015, says HRA Pharma, which has now launched its new ‘Pharmacy’ packs in the UK. The authorisation followed a recommendation by the European Medicines Agency (EMA) in November 2014 to reclassify the emergency hormonal contraceptive.

Ulipristal acetate can be used to prevent unintended pregnancy if taken within 120 hours (five days) of unprotected intercourse or if a contraceptive method has failed. It works by preventing or delaying ovulation and works best if taken within 24 hours.

“ellaOne is the most effective emergency hormonal contraceptive available,” says Tony Fraser, general manager of HRA Pharma UK and Ireland, based in London. “I am delighted to see the new P packs going out for sale under the supervision of a pharmacist direct to those in need.”

Levonorgestrel-containing emergency contraceptives are already available without prescription in most EU countries and are licensed for use up to 72 hours after unprotected intercourse or contraceptive failure.

Following the reclassification recommendation by the EMA’s Committee for Medicinal Products for Human Use (CHMP), the Royal Pharmaceutical Society welcomed the move, noting that it widened the options for women at risk of unplanned pregnancy.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20068393

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.